Amniotic Membrane Market Report 2025

The amniotic membrane market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing patient demand, medical advancements, wound healing research, surgical innovations, burn treatment evolution.

The amniotic membrane market size is expected to see rapid growth in the next few years. It will grow to $2.86 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to expanding applications, regenerative medicine growth, rising prevalence of chronic diseases, aging population demographics, clinical trials and research. Major trends in the forecast period include patient-centric healthcare, focus on anti-inflammatory effects, clinical validation and research, biological dressing innovations, customized and personalized treatments.

The anticipated rise in transplant procedures is expected to accelerate the growth of the amniotic membrane market in the near future. Transplantation involves the surgical transfer of tissue or an organ from one person (the donor) to another recipient. The amniotic membrane is employed in a variety of transplant surgeries. For instance, the NHS Blood and Transplant Annual Report and Accounts 2022-23 reported a 2% increase in the number of donors and a 5% rise in transplants in the UK during 2022-23 compared to the prior year. Thus, the increasing volume of transplants is driving the development of the amniotic membrane market.

The rising prevalence of chronic diseases is anticipated to drive the growth of the amniotic membrane market in the future. Chronic diseases are illnesses that persist for three months or longer and may worsen over time. The amniotic membrane's unique characteristics, including its anti-inflammatory and regenerative properties, make it effective in managing chronic conditions, minimizing complications, and repairing tissue damage. Its versatility allows it to be used across various medical fields, addressing the demand for effective treatments for chronic diseases. For example, a report from the World Health Organization, a United Nations agency based in Switzerland, projects that by 2050, there will be over 35 million new cancer cases, reflecting a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the amniotic membrane market.

Major players in the amniotic membrane market are strategically focusing on the development of new surgical wound solutions to gain a competitive advantage. Surgical wounds are intentional incisions or injuries made during surgical procedures. An example of this trend is observed in the actions of MiMedx Group Inc., a biomedical company based in Georgia. In September 2022, the company launched AMNIOEFFECT, a tri-layer PURION processed human tissue allograft specifically designed for surgical procedures. This product supports the healing cascade by facilitating the development of granulation tissue. Comprising the amnion, intermediate, and chorion membrane layers of the placenta, AMNIOEFFECT enhances MiMedx's Surgical Recovery product portfolio. It provides a biocompatible human extracellular matrix (ECM) and retains over 300 regulatory proteins. The tissue offers superior handling characteristics, enabling surgeons to secure tissue in place with sutures for addressing surgical wounds.

Major companies in the amniotic membrane market are also investing in the development of new allografts to maintain a competitive edge. Allografts involve the transplantation of tissues or organs from one individual (the donor) to another individual (the recipient) within the same species. Amnio Technology LLC, a US-based biotechnology company, exemplifies this trend. In February 2022, the company launched two innovative dual-layer amniotic tissue allografts - PalinGen Dual-Layer Membrane and Dual Layer PalinGen X-Membrane. These products, designed for patients with non-healing acute and chronic wounds, complex surgical wounds, and burns, offer enhanced durability and slower resorption. Their dual-layered structure allows for unidirectional application with two outward-facing epithelial sides, contributing to improved wound management. Developed through the proprietary Advantek process, these allografts preserve the natural tissue's extracellular matrix components and regulatory proteins.

In March 2022, Théa Pharma Inc., a pharmaceutical company based in the U.S., acquired Akorn Operating Company LLC for an undisclosed sum. This acquisition is part of Théa Pharma's strategy to strengthen its presence in the U.S. eye care market by expanding its product range for eye care professionals and improving access to innovative treatments for conditions such as glaucoma, dry eye, allergies, and inflammation. Akorn Operating Company LLC specializes in the development, manufacturing, and marketing of both branded and generic pharmaceuticals.

Major companies operating in the amniotic membrane market include Alliqua BioMedical Inc., Amnio Technology LLC, Applied Biologics LLC, Human Regenerative Technologies LLC, Rivela DermaScience, MiMedx Group Inc., Skye Biologics Inc., Amniox Medical Inc., Integra LifeSciences Co., Organogenesis Holdings Inc., Bio-Tissue Inc., Stryker Corporation, Osiris Therapeutics Inc., Tissue-Tech Inc., DermaSciences Inc., Laboratoire CCD, VIVEX Biologics Inc., Merakris Therapeutics Inc., Thea Pharma Inc., Celularity Inc., Corza Ophthalmology, LifeCell International Pvt. Ltd., Smith & Nephew, RTI Surgical, BioLab Sciences, Allosure Inc., FzioMed Inc.

North America was the largest region in the amniotic membrane market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amniotic membrane market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amniotic membrane market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The amniotic membrane, situated as the deepest layer of the placenta, comprises an avascular stromal matrix and a substantial foundation membrane. With numerous applications in regenerative medicine, it serves as a dressing in various surgical subspecialties to facilitate wound healing and reduce inflammation.

The primary products derived from the amniotic membrane include cryopreserved amniotic membrane and lyophilization amniotic membrane. Lyophilization amniotic membrane involves the preservation process of freezing something rapidly and then subjecting it to a vacuum to remove ice. These products find diverse applications in surgical wounds, ophthalmology, and other medical fields. They are utilized in hospitals, ambulatory surgical centers (ASCs), specialty clinics, as well as research and academic institutes.

The amniotic membrane market research report is one of a series of new reports that provides amniotic membrane market statistics, including amniotic membrane industry global market size, regional shares, competitors with an amniotic membrane market share, detailed amniotic membrane market segments, market trends and opportunities, and any further data you may need to thrive in the amniotic membrane industry. This amniotic membrane market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amniotic membrane market consists of sales of epithelium, basement membrane, and stroma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.